| Publication |
2012.
|
| Summary/Abstract |
Recent cases of counterfeit and contaminated medication have raised concerns about the integrity of the US supply chain of pharmaceuticals. Moreover, Shortage in oncology drug have highlighted a weak domestic production capacity for essential medication. The FDA and the Pew Charitable Trusts have published analyses of the problem as they relate to the US's regulatory system and healthcare industry. These issues also represent a potential national security threat.
|